Stock RV6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Charles River Laboratories International, Inc. Xetra

Equities

RV6

US1598641074

Delayed Xetra
Other stock markets
 09:05:34 10/08/2022 pm IST 		5-day change 1st Jan Change
215.8 EUR -2.40% Intraday chart for Charles River Laboratories International, Inc. -.--% -.--%
17/06 Charles River Laboratories, Captain T Cell Enter Manufacturing Deal MT
17/06 Charles River Laboratories International, Inc and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy CI

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company benefits from high valuations in earnings multiples.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-.--% 10.81B -
MODERNA, INC. Stock Moderna, Inc.
+35.14% 51.07B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.43% 38.78B
B
LONZA GROUP AG Stock Lonza Group AG
+35.88% 38.61B
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.62% 27.32B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.63% 26.35B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-17.77% 19.46B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+40.52% 13.58B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.70% 12.46B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.41% 11.75B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. RV6 Stock
  5. Ratings Charles River Laboratories International, Inc.